Erratum to Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 16:1–7. DOI: 10.1177/11795484221119316
Authors: Rosie S. Jones1, Patricia S. Smith1, Paul H. Berg1, Amparo de la Peña1, Paul P. Cook2, Imad Shawa3, Kathleen M. Kioussopoulos3, Yu Hu1, Robert J. Schott1*
1Eli Lilly and Company, Indianapolis, IN, USA
2East Carolina University Brody School of Medicine, Greenville, NC, USA
3Franciscan Alliance, Indianapolis, IN, USA
*Corresponding Author: Robert Schott, Sangamo Therapeutics, Richmond, California, USA. Email: rschott@sangamo.com
Correction
After publication of the original article,1 we were notified that an author, Amparo de la Peña, was missing from the PDF version due to an administrative error by SAGE Publications. The revised list of author names has now been corrected in the article PDF and read as follows:
Rosie S. Jones1, Patricia S. Smith1, Paul H. Berg1, Amparo de la Peña1, Paul P. Cook2, Imad Shawa3, Kathleen M. Kioussopoulos3, Yu Hu1, Robert J. Schott1*
1Eli Lilly and Company, Indianapolis, IN, USA
2East Carolina University Brody School of Medicine, Greenville, NC, USA
3Franciscan Alliance, Indianapolis, IN, USA
*Current affiliation: Sangamo Therapeutics, Richmond, California, USA; all work carried out while at Eli Lilly and Company
Reference
- 1.Jones RS, Smith PS, Berg PH, et al. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. January 2022. doi: 10.1177/11795484221119316 [DOI] [PMC free article] [PubMed] [Google Scholar]